Benzinga | Oct 12, 2020 12:39PM EDT

JP Morgan Initiates Coverage On Dyne Therapeutics with Overweight Rating, Announces Price Target of $27

JP Morgan analyst Anupam Rama initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating and announces Price Target of $27.